Table 4.
Clinical outcomes
| VN + CP | VN + PT | Rate ratioa | |
|---|---|---|---|
| KDIGO-AKI at 14 days, n (%) | |||
| Crude | 129 (29.2) | 125 (42.1) | 1.59 (1.25, 2.04) |
| IPTW | 1.34 (1.01, 1.77) | ||
| KDIGO-AKI stage 2/3 at 14 days, n (%) | |||
| Crude | 67 (15.2) | 60 (20.2) | 1.47 (1.04, 2.09) |
| IPTW | 1.10 (0.73, 1.67) | ||
| AKI requiring dialysis at 14 days, n (%)b | |||
| Crude | 26 (5.9) | 14 (4.7) | 0.89 (0.46, 1.69) |
| IPTW | 0.63 (0.31, 1.29) | ||
| Mortality at 30 days, n (%) | |||
| Crude | 151 (34.2) | 136 (45.8) | 1.53 (1.21, 1.92) |
| IPTW | 1.05 (0.79, 1.41) | ||
VN + PT vancomycin + piperacillin–tazobactam, VN + CP vancomycin + cefepime
aRate ratio estimated from Poisson regression accounting for person-time at risk
bAKI events occurring through day 14 were followed for 7 days from the onset of AKI to observe for dialysis initiation